MedPath

Active Surveillance for Cancer of the Prostate (ASCaP)

Recruiting
Conditions
Prostate Cancer
Interventions
Other: Active surveillance
Registration Number
NCT00949819
Lead Sponsor
Jonsson Comprehensive Cancer Center
Brief Summary

Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.

Detailed Description

This protocol is not designed as a formal clinical trial, but rather an observational protocol; no treatments and no randomization are included. Longitudinally, specimens and clinical data will be collected to provide information on the following:

* Imaging studies of the prostate

* Rates of curative intervention

* Measures of tumor recurrence/progression

* Disease specific survival

* Overall survival

* Clinical data to track Quality of Life

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
462
Inclusion Criteria
  1. Histologically confirmed adenocarcinoma of the prostate.
  2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
  3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
  4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.
  5. Patient consent has been obtained according to local Institutional Review Board .
  6. Patient is accessible and compliant for follow-up.
Exclusion Criteria
  1. Unwillingness or inability to undergo serial prostate biopsy.
  2. Overall life expectancy less than 2 years
  3. Advanced prostate cancer

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
no treatmentActive surveillanceMen with previously untreated, early stage prostate cancer.
Primary Outcome Measures
NameTimeMethod
Discover and confirm clinical parameters that predict aggressive disease as defined by pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.Interim data analysis will be made every year
Secondary Outcome Measures
NameTimeMethod
Determine the clinical predictors of disease progression. Measure the recurrence-free, disease-specific, and overall survival of men on active surveillance for clinically localized prostate cancer. Determine factors that lead to active interventionInterim data analysis will be done each year

Trial Locations

Locations (1)

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath